Hypertension in aortic stenosis implications for left ventricular structure and cardiovascular events

Hypertension

Volumn 60, Issue 1, 2012, Pages 90-97

  Rieck, Åshild E ^a   Cramariuc, Dana ^b   Boman, Kurt ^c   Gohlke Bärwolf, Christa ^d   Staal, Eva M ^e   Lønnebakken, Mai Tone ^a,b   Rossebø, Anne B ^f   Gerdts, Eva ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UMEÅ UNIVERSITY   (Sweden)

^d UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antihypertensive agents; Aortic valve stenosis; Echocardiography; Hypertension; Prognosis

Indexed keywords

EZETIMIBE PLUS SIMVASTATIN; ANTIHYPERTENSIVE AGENT; AZETIDINE DERIVATIVE; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; SIMVASTATIN;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; AORTA VALVE STENOSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; ECHOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICS;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; AORTIC VALVE STENOSIS; AZETIDINES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN;

EID: 84865830621     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.194878     Document Type: Article

References (39)

1. Rieck AE, Cramariuc D, Staal EM, Rossebo AB, Wachtell K, Gerdts E. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens. 2010;28:377-383.
2. Pate GE. Association between aortic stenosis and hypertension. J Heart Valve Dis. 2002;11:612-614.
3. Linhartova K, Filipovsky J, Cerbak R, Sterbakova G, Hanisova I, Beranek V. Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters. Blood Press. 2007;16:122-128.
4. Antonini-Canterin F, Huang G, Cervesato E, Faggiano P, Pavan D, Piazza R, Nicolosi GL. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension. 2003;41:1268-1272.
5. De Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol. 1995;25:1056-1062.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
7. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
8. Rossebo AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Barwolf C, Holme I, Kesaniemi VA, Malbecq W, Nienaber C, Ray S, Skjaerpe T, Wachtell K, Willenheimer R. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study. Am J Cardiol. 2007;99:970-973.
9. Mancia G, Laurent S, Gabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
10. Lund BP, Gohlke-Barwolf C, Cramariuc D, Rossebo AB, Rieck AE, Gerdts E. Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy). Am J Cardiol. 2010;105:1456-1460.
11. Cramariuc D, Rieck AE, Staal EM, Wachtell K, Eriksen E, Rossebo AB, Gerdts E. Factors influencing left ventricular structure and stresscorrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy). Am J Cardiol. 2008;101:510-515.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
13. Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quinones M. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1-23.
14. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7-11.
15. De Simone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Alderman MH, Laragh JH. Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension. J Am Coll Cardiol. 1994;23:1444-1451.
16. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, De DO, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992;20:1251-1260.
17. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol. 1996;28:751-756.
18. Bahlmann E, Cramariuc D, Gerdts E, Gohlke-Baerwolf C, Nienaber CA, Eriksen E, Wachtell K, Chambers J, Kuck KH, Ray S. Impact of pressure recovery on echocardiographic assessment of asymptomatic aortic stenosis: a SEAS substudy. J Am Coll Cardiol Cardiovasc Imaging. 2010;3:555-562.
19. Lebowitz NE, Bella JN, Roman MJ, Liu JE, Fishman DP, Paranicas M, Lee ET, Fabsitz RR, Welty TK, Howard BV, Devereux RB. Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. J Am Coll Cardiol. 2000;36:461-467.
20. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, Pibarot P. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005;46:291-298.
21. Cramariuc D, Cioffi G, Rieck AE, Devereux RB, Staal EM, Ray S, Wachtell K, Gerdts E. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. J Am Coll Cardiol Cardiovasc Imaging. 2009;2:390-399.
22. Burwash IG, Hay KM, Chan KL. Hemodynamic stability of valve area, valve resistance, and stroke work loss in aortic stenosis: a comparative analysis. J Am Soc Echocardiogr. 2002;15:814-822.
23. Burwash IG, Pearlman AS, Kraft CD, Miyake-Hull C, Healy NL, Otto CM. Flow dependence of measures of aortic stenosis severity during exercise. J Am Coll Cardiol. 1994;24:1342-1350.
24. Ganau A, Devereux RB, Roman MJ, De SG, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
25. Bermejo J. The effects of hypertension on aortic valve stenosis. Heart. 2005;91:280-282.
26. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
27. Gerdts E, Cramariuc D, De Simone G, Wachtell K, Dahlof B, Devereux RB. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE Study). Eur J Echocardiogr. 2008;9:809-815.
28. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-64.
29. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
30. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease: part 1-prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
31. Baguet JP, Barone-Rochette G, Mallion JM. European Society of Hypertension scientific newsletter: hypertension and coronary heart disease. J Hypertens. 2006;24:2323-2325.
32. Pibarot P, Dumesnil JG. Assessment of aortic stenosis severity: check the valve but don't forget the arteries Heart. 2007;93:780-782.
33. Galderisi M, De SG, Cicala S, De SL, D'Errico A, Caso P, De DO. Coronary flow reserve in hypertensive patients with appropriate or inappropriate left ventricular mass. J. Hypertens. 2003;21:2183-2188.
34. Chockalingam A, Venkatesan S, Subramaniam T, Jagannathan V, Elangovan S, Alagesan R, Gnanavelu G, Dorairajan S, Krishna BP, Chockalingam V. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). Am Heart J. 2004;147:E19.
35. O'Brien KD, Zhao XQ, Shavelle DM, Caulfield MT, Letterer RA, Kapadia SR, Probstfield JL, Otto CM. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004;52:185-191.
36. Nadir MA, Wei L, Elder DH, Libianto R, Lim TK, Pauriah M, Pringle SD, Doney AD, Choy AM, Struthers AD, Lang CC. Impact of reninangiotensin system blockade therapy on outcome in aortic stenosis. J Am Coll Cardiol. 2011;58:570-576.
37. Aurigemma GP, Keaney JF Jr. Renin-angiotensin system inhibition for aortic stenosis "A II, Brute?" J Am Coll Cardiol. 2011;58:577-580.
38. De Simone G, Roman MJ, Koren MJ, Mensah GA, Ganau A, Devereux RB. Stroke volume/pulse pressure ratio and cardiovascular risk in arterial hypertension. Hypertension. 1999;33:800-805.
39. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.